Join to View Full Profile
1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000
Dr. Moyo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2017- Vanderbilt University Medical CenterResidency, Internal Medicine, 2010 - 2012
University of North Carolina at Chapel Hill School of MedicineClass of 2010
Certifications & Licensure
TN State Medical License 2017 - 2026
NC State Medical License 2019 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.Reem Karmali, Geoffrey Shouse, Pallawi Torka, Tamara K Moyo, Jason Romancik
Blood Cancer Journal. 2025-03-26 - Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic c...Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim
Blood Cancer Journal. 2025-03-26 - 1 citationsEvaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice.Nilanjan Ghosh, Ashley Matusz-Fisher, Rupali Bose, Danielle Boselli, Gray Magee
JCO Oncology Practice. 2024-11-18
Abstracts/Posters
- Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) PatientsTamara Moyo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation CohortTamara Moyo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology AssociationJune 1st, 2018
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 58th American Society of Hematology Annual MeetingNovember 3rd, 2016
Study Identifies New Culprit in Lung Cancer DevelopmentJanuary 27th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
